ArticleInternational cancer conference journal2025

Conversion surgery following zolbetuximab-based chemotherapy for CLDN18.2-positive gastroesophageal junction cancer.

Yuki Ushimaru et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.